MAPT and Alzheimer disease: In AD diagnostic research, biomarkers such as the ratio of Aβ42/Aβ40 in plasma and p-tau proteins (p-tau181, p-tau231, and p-tau217) have demonstrated high diagnostic accuracy, further supporting their potential as noninvasive diagnostic tools.